These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25358597)

  • 21. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.
    Broussas M; Dupont J; Gonzalez A; Blaecke A; Fournier M; Corvaïa N; Goetsch L
    Int J Cancer; 2009 May; 124(10):2281-93. PubMed ID: 19165858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
    Zuo Q; Luo RC
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
    Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
    MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor.
    Girnita A; Zheng H; Grönberg A; Girnita L; Ståhle M
    Oncogene; 2012 Jan; 31(3):352-65. PubMed ID: 21685939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
    Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
    Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
    Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
    Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.
    Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
    J Biol Chem; 2005 Jul; 280(26):24412-9. PubMed ID: 15878855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
    Kang J; Guo Z; Zhang H; Guo R; Zhu X; Guo X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
    Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth.
    Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
    Cancer Res; 2021 Jan; 81(2):501-514. PubMed ID: 33158816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
    Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
    Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes.
    Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
    Oncogene; 2017 Oct; 36(41):5734-5744. PubMed ID: 28581517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
    Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
    Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.